Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Diaxonhit SA issues FY 2014 sales guidance and updates on FY 2014 plans


Wednesday, 26 Mar 2014 02:30am EDT 

Diaxonhit SA:Sees sales growth in FY 2014.FY 2013 sales 31.2 million euros.FY 2014 sales 32.18 million euros - Thomson Reuters I/B/E/S Estimates.To launch Allomap in FY 2014.To start validation study of Dx15 in FY 2014. 

Latest Developments for Diaxonhit SA